vs
OLIN Corp（OLN）与瑞思迈（RMD）财务数据对比。点击上方公司名可切换其他公司
OLIN Corp的季度营收约是瑞思迈的1.2倍（$1.7B vs $1.4B），瑞思迈净利率更高（27.6% vs -8.6%，领先36.2%），瑞思迈同比增速更快（11.0% vs -0.4%），过去两年瑞思迈的营收复合增速更高（9.0% vs 0.9%）
奥林公司是美国知名制造企业，主营弹药、氯气及氢氧化钠产品。其历史可追溯至1892年成立的两家企业：富兰克林·W·奥林创立的公平火药公司，以及马西森碱业公司。过往奥林旗下化工厂曾发生安全事故，对员工及周边居民健康造成风险。
瑞思迈是一家起源于澳大利亚、总部位于美国加利福尼亚州圣迭戈的医疗设备企业，主打可接入云端的呼吸类医疗设备，用于治疗睡眠呼吸暂停、慢性阻塞性肺病等呼吸道疾病，新冠疫情期间曾大量生产呼吸机等设备助力患者救治。
OLN vs RMD — 直观对比
营收规模更大
OLN
是对方的1.2倍
$1.4B
营收增速更快
RMD
高出11.3%
-0.4%
净利率更高
RMD
高出36.2%
-8.6%
两年增速更快
RMD
近两年复合增速
0.9%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.7B | $1.4B |
| 净利润 | $-143.2M | $392.6M |
| 毛利率 | 1.9% | 61.8% |
| 营业利润率 | -9.4% | 34.6% |
| 净利率 | -8.6% | 27.6% |
| 营收同比 | -0.4% | 11.0% |
| 净利润同比 | -1517.8% | 13.9% |
| 每股收益（稀释后） | $-1.25 | $2.68 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OLNRMD
| Q4 25 | $1.7B | $1.4B | ||
| Q3 25 | $1.7B | $1.3B | ||
| Q2 25 | $1.8B | $1.3B | ||
| Q1 25 | $1.6B | $1.3B | ||
| Q4 24 | $1.7B | $1.3B | ||
| Q3 24 | $1.6B | $1.2B | ||
| Q2 24 | $1.6B | $1.2B | ||
| Q1 24 | $1.6B | $1.2B |
净利润OLNRMD
| Q4 25 | $-143.2M | $392.6M | ||
| Q3 25 | $43.7M | $348.5M | ||
| Q2 25 | $-2.8M | $379.7M | ||
| Q1 25 | $1.2M | $365.0M | ||
| Q4 24 | $10.1M | $344.6M | ||
| Q3 24 | $-25.2M | $311.4M | ||
| Q2 24 | $72.3M | $292.2M | ||
| Q1 24 | $47.8M | $300.5M |
毛利率OLNRMD
| Q4 25 | 1.9% | 61.8% | ||
| Q3 25 | 10.7% | 61.5% | ||
| Q2 25 | 7.9% | 60.8% | ||
| Q1 25 | 9.0% | 59.3% | ||
| Q4 24 | 9.4% | 58.6% | ||
| Q3 24 | 8.5% | 58.6% | ||
| Q2 24 | 14.5% | 58.5% | ||
| Q1 24 | 12.7% | 57.9% |
营业利润率OLNRMD
| Q4 25 | -9.4% | 34.6% | ||
| Q3 25 | 4.8% | 33.4% | ||
| Q2 25 | 2.0% | 33.7% | ||
| Q1 25 | 2.7% | 33.0% | ||
| Q4 24 | 2.8% | 32.5% | ||
| Q3 24 | 1.0% | 31.6% | ||
| Q2 24 | 8.3% | 31.2% | ||
| Q1 24 | 5.9% | 31.3% |
净利率OLNRMD
| Q4 25 | -8.6% | 27.6% | ||
| Q3 25 | 2.6% | 26.1% | ||
| Q2 25 | -0.2% | 28.2% | ||
| Q1 25 | 0.1% | 28.3% | ||
| Q4 24 | 0.6% | 26.9% | ||
| Q3 24 | -1.6% | 25.4% | ||
| Q2 24 | 4.4% | 23.9% | ||
| Q1 24 | 2.9% | 25.1% |
每股收益（稀释后）OLNRMD
| Q4 25 | $-1.25 | $2.68 | ||
| Q3 25 | $0.37 | $2.37 | ||
| Q2 25 | $-0.01 | $2.58 | ||
| Q1 25 | $0.01 | $2.48 | ||
| Q4 24 | $0.10 | $2.34 | ||
| Q3 24 | $-0.21 | $2.11 | ||
| Q2 24 | $0.62 | $1.97 | ||
| Q1 24 | $0.40 | $2.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.6M | $1.4B |
| 总债务越低越好 | $2.8B | $403.9M |
| 股东权益账面价值 | $1.8B | $6.3B |
| 总资产 | $7.3B | $8.5B |
| 负债/权益比越低杠杆越低 | 1.55× | 0.06× |
8季度趋势，按日历期对齐
现金及短期投资OLNRMD
| Q4 25 | $167.6M | $1.4B | ||
| Q3 25 | — | $1.4B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $932.7M | ||
| Q4 24 | $175.6M | $521.9M | ||
| Q3 24 | — | $426.4M | ||
| Q2 24 | — | $238.4M | ||
| Q1 24 | — | $237.9M |
总债务OLNRMD
| Q4 25 | $2.8B | $403.9M | ||
| Q3 25 | $3.0B | $408.7M | ||
| Q2 25 | $3.0B | $658.4M | ||
| Q1 25 | $3.0B | $663.1M | ||
| Q4 24 | $2.7B | $662.9M | ||
| Q3 24 | $2.8B | $667.6M | ||
| Q2 24 | $2.8B | $697.3M | ||
| Q1 24 | $2.7B | $997.0M |
股东权益OLNRMD
| Q4 25 | $1.8B | $6.3B | ||
| Q3 25 | $2.0B | $6.1B | ||
| Q2 25 | $2.0B | $6.0B | ||
| Q1 25 | $2.0B | $5.5B | ||
| Q4 24 | $2.0B | $5.3B | ||
| Q3 24 | $2.1B | $5.2B | ||
| Q2 24 | $2.1B | $4.9B | ||
| Q1 24 | $2.2B | $4.6B |
总资产OLNRMD
| Q4 25 | $7.3B | $8.5B | ||
| Q3 25 | $7.6B | $8.3B | ||
| Q2 25 | $7.7B | $8.2B | ||
| Q1 25 | $7.7B | $7.6B | ||
| Q4 24 | $7.6B | $7.1B | ||
| Q3 24 | $7.5B | $7.2B | ||
| Q2 24 | $7.7B | $6.9B | ||
| Q1 24 | $7.6B | $6.8B |
负债/权益比OLNRMD
| Q4 25 | 1.55× | 0.06× | ||
| Q3 25 | 1.52× | 0.07× | ||
| Q2 25 | 1.52× | 0.11× | ||
| Q1 25 | 1.50× | 0.12× | ||
| Q4 24 | 1.34× | 0.13× | ||
| Q3 24 | 1.34× | 0.13× | ||
| Q2 24 | 1.31× | 0.14× | ||
| Q1 24 | 1.24× | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $321.2M | $339.7M |
| 自由现金流经营现金流 - 资本支出 | — | $311.2M |
| 自由现金流率自由现金流/营收 | — | 21.9% |
| 资本支出强度资本支出/营收 | — | 2.0% |
| 现金转化率经营现金流/净利润 | — | 0.87× |
| 过去12个月自由现金流最近4个季度 | — | $1.8B |
8季度趋势，按日历期对齐
经营现金流OLNRMD
| Q4 25 | $321.2M | $339.7M | ||
| Q3 25 | $26.7M | $457.3M | ||
| Q2 25 | $212.3M | $538.8M | ||
| Q1 25 | $-86.0M | $578.7M | ||
| Q4 24 | $141.7M | $308.6M | ||
| Q3 24 | $189.9M | $325.5M | ||
| Q2 24 | $90.6M | $440.1M | ||
| Q1 24 | $81.0M | $402.0M |
自由现金流OLNRMD
| Q4 25 | — | $311.2M | ||
| Q3 25 | $-44.4M | $414.4M | ||
| Q2 25 | — | $508.2M | ||
| Q1 25 | $-147.4M | $557.9M | ||
| Q4 24 | $90.7M | $288.0M | ||
| Q3 24 | $146.6M | $307.7M | ||
| Q2 24 | $34.1M | $415.2M | ||
| Q1 24 | $36.7M | $380.8M |
自由现金流率OLNRMD
| Q4 25 | — | 21.9% | ||
| Q3 25 | -2.6% | 31.0% | ||
| Q2 25 | — | 37.7% | ||
| Q1 25 | -9.0% | 43.2% | ||
| Q4 24 | 5.4% | 22.5% | ||
| Q3 24 | 9.2% | 25.1% | ||
| Q2 24 | 2.1% | 33.9% | ||
| Q1 24 | 2.2% | 31.8% |
资本支出强度OLNRMD
| Q4 25 | — | 2.0% | ||
| Q3 25 | 4.2% | 3.2% | ||
| Q2 25 | — | 2.3% | ||
| Q1 25 | 3.7% | 1.6% | ||
| Q4 24 | 3.1% | 1.6% | ||
| Q3 24 | 2.7% | 1.5% | ||
| Q2 24 | 3.4% | 2.0% | ||
| Q1 24 | 2.7% | 1.8% |
现金转化率OLNRMD
| Q4 25 | — | 0.87× | ||
| Q3 25 | 0.61× | 1.31× | ||
| Q2 25 | — | 1.42× | ||
| Q1 25 | -71.67× | 1.59× | ||
| Q4 24 | 14.03× | 0.90× | ||
| Q3 24 | — | 1.05× | ||
| Q2 24 | 1.25× | 1.51× | ||
| Q1 24 | 1.69× | 1.34× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OLN
| Chlorinechlorinederivativesandothercoproducts | $456.2M | 27% |
| Causticsoda | $400.2M | 24% |
| Militaryandlawenforcement | $304.6M | 18% |
| Epoxyresins | $194.9M | 12% |
| Aromaticsandallylics | $164.4M | 10% |
| Commercial | $144.8M | 9% |
RMD
| Sleep And Breathing Health | $1.3B | 88% |
| Residential Care Software | $166.9M | 12% |
